undamentalytics Newsletter
Sign in

Irhythm Holdings, Inc. income statement

In fiscal 2025, Irhythm Holdings, Inc. reported revenue of $747m, up 26.2% on the year before, operating income of −$57.4m (a -7.7% margin) and net income of −$44.6m, or −$1.39 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue22366499147215265323411493592747825
Cost of revenue11152128395270109129161184220236
Gross profit11214371108162195214282332408527590
Research and development66713213741394760718583
Selling, general and administrative20375285133180197275322386419493514
Operating income−15−22−16−28−46−55−44−100−114−125−116−57−25
Interest expense1133322144131313
Income before tax——−21−30−50−55−44−101−116−123−113−44−13
Income tax0000000001111
Net income−16−23−21−30−50−55−44−101−116−123−113−45−14
Diluted EPS−$3.01−$4.14−$3.95−$1.31−$2.11−$2.16−$1.58−$3.46−$3.88−$4.04−$3.63−$1.39−$0.43
Diluted shares (average)5m6m5m23m24m25m28m29m30m31m31m32m32m
EBITDA−15−21−15−26−43−51−37−90−100−109−95−37−4

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: IRTC vs OFIXATEC vs IRTCIRTC vs MYGN

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Irhythm Holdings, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Irhythm Holdings, Inc.